Abstract

COSTANZO, Luca et al. Coronavirus disease-19 pneumonia: The impact of coagulopathy. Rev. mex. angiol. [online]. 2020, vol.48, n.2, pp.35-37.  Epub Aug 23, 2021. ISSN 2696-130X.  https://doi.org/10.24875/rma.m20000013.

The development of coagulopathy is emerging as one of the most significant poor prognostic features in coronavirus disease (COVID)-19 pneumopathy. D-dimer, a protein product of fibrin degradation, has been found elevated in the most severe cases and correlated to mortality. Potentially involved factors in the impairment of coagulation caused by viral infection include the dysregulated inflammatory response, platelet, and endothelial dysfunction with impaired fibrinolysis. Heparin is an anticoagulant molecule that also showed anti-inflammatory properties and a potential antiviral effect. The use of low-molecular-weight heparin could prevent thromboembolic complications in COVID-19 pneumopathy. However, the correct timing of prophylaxis according to the stage of COVID-19 disease and the appropriate therapeutic dosage to use in severe cases needs further researches.

Keywords : Coronavirus disease-19; Thrombosis; Coagulopathy; D-dimer; Low-molecular-weight heparin.

        · abstract in Spanish     · text in English     · English ( pdf )